Group items tagged

Fungicides are biological active substances or biocides that kill specific fungal species or fungi. A fungicide restricts their proliferation. Fungi are known to cause serious economic damages in agriculture, causing financial losses, quality, and crop loss. Increasing demand for food is expected to propel growth of the seed treatment fungicides market. For instance, according to Food and Agriculture Organization, Asia Pacific needs to increase their food production by up to 77% by 2050 to meet food demand of increasing population. Moreover, decrease in arable land is also expected to aid in growth of the market. For instance, according to the study 'Will Limited Land, Water, and Energy Control Human Population Numbers in the Future', published in the journal Human Ecology, the amount of arable land available per person will decrease to 1500m² by 2050 from 4000m² in 1961. Approval of new pesticides and fungicides is expected to offer lucrative growth opportunities for players in the seed treatment fungicides market. For instance, in December 2019, The U.S. Environmental Protection Agency approved the use of 10 pesticide products on hemp in time for the 2020 growing season, which include nine Biopesticides, under the Federal Insecticide, Fungicide and Rodenticide Act. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/03/increasing-demand-for-food-and-approval.html

Chronic lymphocytic leukemia is a cancerous disease in which cancer cells begin to multiply in the lymph cells. CLL is aggressive cancer that invades the lymphatic system and attacks healthy cells of the immune system. It typically affects the lymph nodes and T cells, although it can also affect any other cells in the human body. The combination of chemotherapy is aimed at destroying cancer cells while at the same time allowing the body's immune system to restore the damaged cells. This allows for a more rapid response to the infection and better overall outcomes. As a result of this combination, chemotherapy is often used to treat several types of cancer at one time. It has been very successful in achieving results against most types of cancer. The targeted drugs are given to make the cancer cells unable to multiply and thus stop their growth. Increasing prevalence of leukemia is expected to drive growth of the global chronic lymphocytic leukemia therapeutics market during the forecast period. According to the American Society of Clinical Oncology (ASCO), chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults aged 19 years and above with 37% of cases. According to the same source, around 21,040 new cases and 4,060 deaths are expected to occur in 2020 due to CLL in the U.S. Furthermore, according to the Leukemia & Lymphoma Society (LLC), in 2020, around 60,530 people are expected to be diagnosed with leukemia in the U.S. Such a high prevalence of CLL and leukemia has increased the demand for necessary therapeutics such as chemotherapy. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/chronic-lymphocytic-leukemia.html

High prevalence of gastric cancer is expected to propel growth of the gastric cancer therapeutics market. For instance, according to The American Cancer Society, the U.S. is estimated to record about 26,560 cases of stomach cancer and about 11,180 people will die from this type of cancer in 2021. Moreover, R&D in oral chemotherapy for the treatment of gastric cancer is also expected to aid in growth of the market. For instance, in January 2021, Ascelia Pharma AB announced the clinical development plan for Oncoral, with which the company has the opportunity to develop a novel oral chemotherapy for the treatment of gastric cancer. Risk factors for gastric cancer may include smoking and a diet of highly processed or salty foods. Thus, high number of smokers is expected to offer lucrative growth opportunities for players in the gastric cancer therapeutics market. For instance, according to the World Health Organization's, May 2020 Update, tobacco leads to over 8 million deaths each year worldwide and over 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/high-prevalence-of-gastric-cancer-and.html

Graft-versus-host disease (GvHD) is a systemic disorder and a common complication after allogeneic hematopoietic stem cell transplant. The condition can be subclassified into acute classic GVHD, persistent, recurrent, or late-onset acute GVHD, classic chronic GVHD, and overlap syndrome. High adoption of hematopoietic stem cell transplantation and increasing prevalence of certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia is expected to propel growth of the graft versus host disease (GvHD) market. For instance, according to Leukemia and Lymphoma Society, 176,200 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019. Moreover, around 30,000 patients undergo allogeneic hematopoietic stem cell transplant annually in the United States, with approximately 20% to 85% developing aGvHD that affects the skin, gut, or liver. Increasing number of clinical trials for graft versus host disease is expected to offer lucrative growth opportunities for players in the graft versus host disease (GvHD) market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/high-adoption-of-hematopoietic-stem.html

Apheresis is an innovative medical procedure where the blood is extracted from the patient's body and then desired blood components (such as platelets, plasma, white cells, and red cells) are separated based on their weight and size. Depending on the cause of apheresis, one of these components is isolated and collected, while the other components are returned to the body. Apheresis is a blood purification procedure performed for blood donation component or for the treatment of disease. It is performed for various diseases such as hematological, autoimmune, renal, cardiovascular, neurological, and more. In apheresis procedure, the centrifuge therapeutic devices are used to separate desired blood components from the donor's blood. These blood components are separated based on their characteristics such as affinity for substance, molecular weight, and size among other factors. The emergence of COVID-19 is expected to propel the growth of the apheresis market. For instance, according to the Food and Drug Control Administration (Gujarat, India), there were 13 plasma apheresis units in the state before the pandemic, now the number has jumped to 28 to meet the requirement of plasma used in convalescent plasma therapy. Moreover, worldwide, as of 9:47am CET, 13 January 2021, there have been 90,054,813 confirmed cases of COVID-19, including 1,945,610 deaths, according to the World Health Organization (WHO). Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/emergence-of-covid-19-is-expected-to.html

Deep brain stimulation is a non-invasive neurosurgical treatment involving the placement of an electronic device called a simulator that emits electronic pulses, into the brain. These pulses are delivered to the area where there is the greatest need for stimulation, in the area known as the cerebral cortex. The purpose of this treatment is to increase brain function and improve brain function. This treatment is often used in conjunction with other procedures and is also very successful when it is used alone. Increasing prevalence of Parkinson's disease is expected to propel growth of the global deep brain stimulation devices market. For instance, according to the study, 'Prevalence of Parkinson's disease (PD) across North America", published in July 2018 in the journal Nature, the number of people suffering from PD is expected to reach 930,000 in 2020 and 1,238,000 in 2030. Increasing number of clinical trials for deep brain stimulation devices is expected to offer lucrative growth opportunities for players in the global deep brain stimulation devices market. For instance, in January 2021, Medtronic plc announced the first enrollment in ADAPT-PD, a trial evaluating the safety and efficacy of adaptive deep brain stimulation in patients with Parkinson's disease. Similarly, in October 2020, Keck Medicine of USC announced to enroll individuals in an international phase 3 clinical trial to examine the safety and effectiveness of deep brain stimulation to treat Alzheimer's. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/increasing-prevalence-of-parkinsons.html

Nurse call system makes an all-in one solution for both your nurse call needs as well as wireless nurse phone calls. These systems have been some of the best in the market these days in that they can incorporate any old piece of hospital equipment into a single unified call center system. With an integrated system, you can now use your pager, digital radio, or even your cell phone to dial in, and you can get live access to your nurses through a large LCD screen. Nurses can use this system at the reception desk or even while on the job. For those who wish to be constantly on the go, the system also features an LCD screen with a large touch pad that makes it easy to navigate and input data. A digital radio, headset, and other necessary hardware are all included in the package for the best experience possible. There are many options to choose from in this type of system, depending on how much you want to spend. The biggest thing to consider is how much you need and whether you want a more basic system, or a more advanced system like a fully integrated one. Each system comes with a long warranty, so if ever there was a time when you needed a system to replace, you are covered. High prevalence of chronic disorders is expected to propel growth of the global nurse call systems market. For instance, according to the study, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition", published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/high-prevalence-of-chronic-disorders-to.html

The history of smartcards in healthcare dates back at least to the late 1990s. At that time, the French government began to offer each patient a small plastic card containing a microchip. Each patient then carries around his or her SmartCard. It serves as a virtual keypad on which to enter healthcare information. Smartcards and their associated software have been around since the time they were first introduced. However, as more healthcare companies became aware of the benefits they could see in implementing them into their business and the advantages they provided, they began to use them themselves. Today, nearly every hospital, doctor's office, pharmacy, nursing home, and other facility have some form of smart card or microprocessor smart card in use. A smart card is simply a magnetic strip that is used to make transactions from one place to another. Market Dynamics Increasing healthcare expenditure is expected to propel growth of the smart cards in healthcare market. For instance, according to The Centers for Medicare & Medicaid Services, the U.S. health spending is projected to reach nearly US$ 6.0 trillion by 2027. Moreover, emergence of Covid-19 has prompted several countries to develop vaccination proofing plans, which is also expected to aid in growth of the market. Digital credentials are expected to play a major role in management of the pandemic. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/emergence-of-covid-19-to-boost-adoption.html

Seasonal influenza is caused by viruses known as influenza A, B, C, and D. These names refer to the four types of viruses, and each has a different way of entering the human body. For example, an A virus can be transmitted through the air, while B is most often transmitted through secretions from the nose or mouth. C is the most commonly caught form of the disease but does not usually spread from person to person. Influenza A viruses are the only influenza viruses known to cause flu pandemics, i.e., global epidemics of flu disease. High prevalence of acute respiratory infections is expected to propel growth of the seasonal influenza vaccines market. For instance, the study, 'Viral and Bacterial Etiologies of Acute Respiratory Infections among Children under 5 Years in Senegal', published in the journal Microbiology Insights, in February 2018, found that adenovirus was the most prevalent (50%) among selected virus species, followed by influenza virus, rhinovirus, enterovirus, and respiratory syncytial virus. Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the seasonal influenza vaccines market. For instance, globally, as of 4:25pm CET, 2 December 2020, there have been 63,360,234 confirmed cases of COVID-19, including 1,475,825 deaths, reported to the World Health Organization. Moreover, many people are getting flu shots along with COVID testing, which is also expected to aid in growth of the market. For instance, in December 2020, Tarrant County, TX, U.S., partnered with pharmacies at Kroger and Tom Thumb to help provide free flu vaccines for uninsured residents. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/emergence-of-covid-19-to-augment-growth.html

Patient monitoring refers to the collection and analysis of medical data from one or more health settings (such as in hospitals or doctor's offices) for use by health care providers and other professionals in order to detect changes in an individual's medical status and to provide treatment options as needed. In health care, patient monitoring is generally the measurement of one or more medical parameters over extended periods of time, usually at different health care settings (such as in doctor's offices or hospitals). Patient monitoring may be implemented in many different health care settings including primary care offices, emergency rooms, doctors' offices, nursing homes, private practices, and government agencies. Most patient monitoring systems contain software that collect and store medical data in a database that is accessible to multiple health care providers and to health care facilities. High prevalence of chronic disorders is expected to propel growth of the global remote patient monitoring devices market over the forecast period. For instance, according to the study, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition", published in the journal Diabetes Research and Clinical Practice, in September 2019, 463 million people are expected to suffer from diabetes in 2019 worldwide and the number is expected to reach 578 million by 2030 and 700 million by 2045. Read More @ https://coherentmarketinsights-blog.blogspot.com/2020/11/high-prevalence-of-chronic-disorders-to.html

Biostimulants are natural or synthetic substances that aid in reducing the dependency on fertilizers. These substances are applied to seeds, plants, and soil in order to increase plant growth, resistance to water and abiotic stresses. Increasing global population has led to focus on boosting crop yield. According to projections by Population Reference Bureau (PRB) included in the 2018 World Population Data Sheet, the world population is expected to reach 9.9 billion by 2050, up 2.3 billion or 29% from an estimated 7.6 billion people in 2018. Moreover, according to according to Food and Agriculture Organization, worldwide food demand is expected to increase by 70% by 2050. Decrease in arable land in various regions has led to has led to various challenges in the agricultural sector. According to the study 'Will Limited Land, Water, and Energy Control Human Population Numbers in the Future', published in the journal Human Ecology, the amount of arable land available per person will decrease to 1500m² by 2050 from 4000m² in 1961. In July 2020, the government of India was expected to announce guidelines to regulate the biostimulants market in the country. Earlier, in July 2019, Europe witnessed several changes regarding definition and classification of these substances. Read More @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/increasing-global-population-and-focus.html

Patient warming devices come in many forms, each designed for a specific purpose. For example, some devices are made for offices that are out of the way or for doctor offices that are smaller in size. In addition, these applications are very easy to operate and can be used without requiring a great deal of training on the part of the patient or the medical professional using the device. However, there are certain devices that are extremely efficient and are recommended by both practitioners and medical associations across the country. An increasing number of surgical procedures is expected to drive the growth of the global patient warming devices market. According to the National Health Statistics Reports, in 2017, around 48.3 million surgical and nonsurgical procedures were performed in the U.S. with around 25.7 million ambulatory surgery procedures being performed in hospitals, while 22.5 million being performed in ambulatory surgery centers (ASCs). Patient warming devices are widely used in surgical procedures, which cover before and after surgery. As a result of this, the demand for patient warming devices has increased significantly. Hence, these factors are expected to drive growth of the global patient warming devices market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/02/patient-warming-devices-market-is.html

Course "Tougher Import Rules for FDA Imports in 2016" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: FDA's and the Customs and Border Patrol Service (CBP) have become increasingly sophisticated and equally demanding in the submission of information and adherence to government procedures. Firm's that fail to understand and properly execute an import and export program find that their shipment is delayed, detained or refused. In 2016 entries must use the Automated Commercial Environment (ACE) entry filing system or face entry refusals and monetary penalties up to $10,000 per offense. A number of other factors can derail the expectation of a seamless import process. The course covers detailed information about the roles and responsibilities of the various parties with an import operation and how to correct the weakest link(s) in the commercial chain. The course will include tips on how to understand FDA's thinking and offer anecdotal examples of FDA's import program curiosities. Why should you attend: What happens when your product is detained? FDA will begin a legal process that can become an expensive business debacle. You must respond fully within short timeframes. This is not the time for you to be on a learning curve. You need to have a plan in place and know what you are doing. The FDA is steadily increasing the legal and prior notice information requirements. If you do not know what those requirements are and you initiate a shipment, your product is figuratively dead in the water. You must be accurate with the import coding information and understand the automated and human review process. If not, you can expect detained shipments. CBP is implemented a new "Automated Commercial Environment" computer program that changes import logistics and information reporting for FDA regulated products. Your shipment may be stopped before it is even loaded at the foreign port. What

A look at disruptive practitioner behavior policies: One of the very important factors needed for a healthcare unit to maintain its decorum and uphold its reputation is the implementation of disruptive practitioner behavior policies. The declaration and implementation of disruptive practitioner behavior policies goes a long way in ensuring that the hospital or healthcare center doesn't lose face. What are disruptive practitioner behavior policies? First, an understanding of disruptive practitioner behavior policies: Disruptive practitioner behavior policies may be termed as the putting in place in a healthcare providing unit a set of policies that are aimed at checking the errant and rude behavior of its staff members towards the patients and other people that use the services rendered by these centers. Who all carry out disruptive practitioner behaviors? Anyone in the healthcare setting can behave in an unbecoming and ungainly fashion with patients or those attending on them. Some of the typical types associated with disruptive practitioner behavior include shouting at them, bullying, intimidating, scolding loudly, being aggressive towards them, gesturing lewdly to them, and so on. This kind of behavior reflects very badly on the healthcare provider. Since there is intense competition in the healthcare providing industry; it is natural for patients to look for other centers when they face this kind of behavior. It is after all human to expect to be treated nicely. If one provider doesn't do that; patients look for other providers. Losing the patient, bad though it is, is not the only loss: When this becomes public, which is all the easier given the extensive reach of the social media; the healthcare unit's name goes for a toss. The role of disruptive practitioner behavior policies It is to curb this kind of behavior that disruptive practitioner behavior policies need to be put in place. Disruptive practitioner behavior policies can go a long way in reining i

Course "Verification vs. Validation - Product Process Software and QMS" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: This course will review the company Master Validation Plan for major key inputs and CGMP deficiencies. It will address the FDA's newer and tougher regulatory stance. This course's aim is to prove "Product Risk Based V&V" by sufficient, targeted and documented risk-based V&V test case elements/scripts. It will teach participants to evaluate its elements against ISO 14971 and ICH Q9 for hazard analysis and product risk management. This course will evaluate different field-tested, U.S. FDA-reviewed V&V protocols; how to employ equipment/process Requirements Specs / DQs, IQs, OQs, and PQs, or their equivalents per ASTM E2500, all against a background of limited company resources. It will review a matrix that simplifies "as-product", in-product", process and equipment, et al, software VT&V, to assure key FDA requirements are not overlooked. While considering the QMS and 21 CFR Part 11; this course will make practical application of these same in two hands-on sessions. Why you should attend: This session helps participants: * Understand Verification and Validation, differences and how they work together; * Discuss recent regulatory expectations; * Know how to document a "risk-based" rationale, and use it in a resource-constrained environment; * Determine key "milestones" and "tasks" in a project; * Locate and document key subject "inputs"; * Compile "generic" Master and Individual Validation Plans; * Learn the key element of a Product V&V File/Protocol; * Understand how to develop Process and/or Production/Test Equipment V&V Files/Protocols; * Get a grasp of basic Test Case construction; * Understand sample sizes and their justification; * Learn the key elements of Software V&V expected by the FDA and how to document; * Deal with hardwa

United States Biopsy Market will cross US$ 17 Billion by the year 2024 owing to the rising prevalence of cancer in the region. According to the World Health Organization, cancer cases are expected to surge 57% worldwide in the next 20 years. Biopsies are most often done to look for cancer; a biopsy is a sample of tissue taken from the body in order to examine it more closely. Further, growing patient awareness and the advancement in the biopsy techniques are also expected to fuel future growth of biopsy market in United States.

Medical sensors are becoming an integral part of medical facilities throughout the world. They enable facilities to monitor all aspects of patient care, from room temperature to vital signs, from pulse rates to oxygen levels, and more. This is a new frontier in patient care that has the potential to dramatically save money and reduce staff fatigue. A medical sensor system can include a variety of different instruments in various formats, ranging from a simple temperature probe attached to a belt clip to highly sophisticated electronic devices capable of monitoring dozens of different parameters. The most common type of medical sensor is a small portable electronic device that is affixed to a person's skin or clothes. These are designed for use in a wide variety of patient care settings including hospitals, rehabilitation centers, and home health care agencies. They are often used by cardiologists and nurses to monitor heart rates and pulse rates as well as measurements of blood pressure and respiration. Increasing demand for medical sensors is expected to propel growth of the global medical sensors market. For instance, 2020, OSI Systems, Inc. announced that its Optoelectronics division received an order to provide optical sensors for use in medical devices from a leading healthcare original equipment manufacturer. Moreover, high prevalence of chronic diseases is also expected to aid in growth of the market. Read more @ https://sachinbhombe.blogspot.com/2021/03/increasing-demand-for-medical-sensors.html

Contract manufacturing is a complex process involved in producing vaccine products. This type of production usually involves the manufacturing of vaccines in a single step. Contract manufacturers usually produce vaccines at their facilities; however, some contract manufacturers also service the field through the provision of workspace and by taking care of the closing storage and final disposition of finished products. Some contract manufacturers specialize in the manufacture of one or few vaccines. Others manufacture vaccines for a number of diseases. Technological developments in biomanufacturing and biotechnology are expected to drive growth of the global vaccine contract manufacturing market. Biotechnology has witnessed significant growth in the recent past in both developed and emerging economies. According to the India Brand Equity Foundation (IBEF), the Indian biotechnology industry was valued at US$ 63 billion in 2019 and is expected to reach US$ 102 billion by 2025, registering a CAGR of 10.9%. Besides, key biotechnology and pharmaceutical companies are focused on launching vaccines for protection against infectious diseases. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/03/vaccine-contract-manufacturing-market.html

Medical devices play an important role in the delivery of many health care services. Medical supplies refer to any item (basic medical products) that is necessary for treating injury or illness. In the medical parlance, medical supplies generally are understood to mean items that are low cost, disposable, easily available, and in high enough quantity so that the buying department has enough standing orders to ensure the supply of the items when they are in demand. Increasing prevalence of chronic diseases across the globe, especially in North America, is expected to propel the growth of the medical supplies market. According to the Centers for Disease Control and Prevention (CDC), chronic diseases such as diabetes, cancer, and heart disease are the leading causes of death and disability in the United States. Moreover, proactive government initiatives, increasing demand for infection control measures to curb the occurrence of hospital-acquired infections, the rising number of surgical procedures, and increasing demand for medical supplies are expected to augment the growth of the medical supplies market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/03/increasing-demand-for-emergency-medical.html

An antacid is simply a substance that neutralizes stomach acids and is typically used to alleviate heartburn, gastric indigestion, or an upset stomach with food. Some antacids are being used in the treatment of diarrhea and constipation. More recently marketed antacids now contain sodium salts of aluminum, magnesium, calcium, or other substances. Antacids are available both over the counter and by prescription. Antacids neutralize stomach acid as they neutralize the alkaline substance in your stomach - the very substance that causes most of the discomfort! In order to be sure that antacids work, it is important to consult your doctor or pharmacist Growing geriatric population suffering GERD, i.e. gastroesophageal reflux disease is expected to drive growth of the global antacid medications market. According to the National Center for Biotechnology Information (NCBI), around 20% of adults in western culture are affected with GERD. According to the same source, the prevalence of GERD in the U.S. was between 18.1% and 27.8% in 2020. GERD is one of the most common gastrointestinal disorders among the geriatric population. According to the World Health Organization (WHO), by 2050, the global population aged 65 years and above is expected to reach around 2 billion increasing from 900 million in 2015. Read More @ https://coherentmarketinsights-blog.blogspot.com/2021/01/antacid-medications-market-is-expanding.html